First Foundation Advisors Acquires 50 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

First Foundation Advisors lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% during the 1st quarter, HoldingsChannel reports. The fund owned 3,109 shares of the biopharmaceutical company’s stock after buying an additional 50 shares during the period. First Foundation Advisors’ holdings in Regeneron Pharmaceuticals were worth $2,992,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock worth $7,762,577,000 after purchasing an additional 39,780 shares in the last quarter. Capital World Investors raised its stake in shares of Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after buying an additional 23,146 shares in the last quarter. Putnam Investments LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 2.1% during the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after acquiring an additional 24,329 shares during the period. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $932,571,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Regeneron Pharmaceuticals by 3.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 620,616 shares of the biopharmaceutical company’s stock valued at $545,081,000 after acquiring an additional 22,558 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded down $3.66 on Friday, hitting $1,063.60. The stock had a trading volume of 452,210 shares, compared to its average volume of 453,015. The stock has a market cap of $117.20 billion, a price-to-earnings ratio of 31.42, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13. The business’s 50 day moving average is $1,025.07 and its two-hundred day moving average is $971.85. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $720.00 and a twelve month high of $1,106.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.17 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on REGN shares. Piper Sandler upped their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the company an “overweight” rating in a research note on Friday. JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Monday, June 17th. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, May 3rd. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, June 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,063.82.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Joseph J. Larosa sold 1,866 shares of the company’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the sale, the executive vice president now owns 37,937 shares in the company, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. Insiders sold a total of 65,074 shares of company stock valued at $64,546,123 over the last quarter. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.